Clinical and biological manifestations of SLE according to AIC at the last follow-up
| Manifestations . | Total n = 79 n (%) . | cITP n = 43 n (%) . | AIHA n = 12 n (%) . | ES n = 24 n (%) . | Median delay from AIC diagnosis, y (min-max) . |
|---|---|---|---|---|---|
| Articular | 34 (43%) | 17 (40%) | 3 (25%) | 14 (58%) | 2.3 (0-13.8) |
| Cutaneous | 34 (43%) | 18 (42%) | 5 (42%) | 11 (46%) | 1.7 (0-15.5) |
| Renal | 10 (13%) | 4 (9%) | 1 (8%) | 5 (21%) | 4.9 (0-10.2) |
| Neurological | 8 (10%) | 3 (7%) | 3 (25%) | 2 (8%) | 0.4 (0-12.9) |
| Thoracic | 6 (8%) | 2 (5%) | 2 (17%) | 2 (8%) | 5.4 (0-10.3) |
| Digestive | 1 (1%) | 0 | 0 | 1 (4%) | NA |
| APS | 2 (3%) | 1 (2%) | 1 (8%) | 0 | NA |
| TTP | 2 (3%) | 0 | 0 | 2 (8%) | NA |
| Anti-dsDNA or anti-Smith Abs | 65 (82%) | 38 (88%) | 9 (75%) | 18 (75%) | 1.1 (0-11.5) |
| Low C3 and/or C4 | 43 (54%) | 18 (42%) | 8 (67%) | 17 (71%) | 0.3 (0-15) |
| Antiphospholipid | 40 (51%) | 22 (51%) | 8 (67%) | 10 (42%) | 0.9 (0-14.5) |
| Leukopenia | 23 (29%) | 11 (26%) | 6 (50%) | 6 (25%) | 0.1 (0-20) |
| Manifestations . | Total n = 79 n (%) . | cITP n = 43 n (%) . | AIHA n = 12 n (%) . | ES n = 24 n (%) . | Median delay from AIC diagnosis, y (min-max) . |
|---|---|---|---|---|---|
| Articular | 34 (43%) | 17 (40%) | 3 (25%) | 14 (58%) | 2.3 (0-13.8) |
| Cutaneous | 34 (43%) | 18 (42%) | 5 (42%) | 11 (46%) | 1.7 (0-15.5) |
| Renal | 10 (13%) | 4 (9%) | 1 (8%) | 5 (21%) | 4.9 (0-10.2) |
| Neurological | 8 (10%) | 3 (7%) | 3 (25%) | 2 (8%) | 0.4 (0-12.9) |
| Thoracic | 6 (8%) | 2 (5%) | 2 (17%) | 2 (8%) | 5.4 (0-10.3) |
| Digestive | 1 (1%) | 0 | 0 | 1 (4%) | NA |
| APS | 2 (3%) | 1 (2%) | 1 (8%) | 0 | NA |
| TTP | 2 (3%) | 0 | 0 | 2 (8%) | NA |
| Anti-dsDNA or anti-Smith Abs | 65 (82%) | 38 (88%) | 9 (75%) | 18 (75%) | 1.1 (0-11.5) |
| Low C3 and/or C4 | 43 (54%) | 18 (42%) | 8 (67%) | 17 (71%) | 0.3 (0-15) |
| Antiphospholipid | 40 (51%) | 22 (51%) | 8 (67%) | 10 (42%) | 0.9 (0-14.5) |
| Leukopenia | 23 (29%) | 11 (26%) | 6 (50%) | 6 (25%) | 0.1 (0-20) |
Abs, antibodies; APS, antiphospholipid syndrome; NA, not available; TTP, thrombotic thrombocytopenic purpura.